Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
hema.to GmbH logo — AI cytometry to advance precision immune medicine

hema.to GmbH

AI cytometry to advance precision immune medicine

Founded 2021 Germany Germany 18 employees Seed Total: $7.20M AI, Health Care

General Information

Company Name hema.to GmbH
Founded Year 2021
Location Germany Germany +1
Employees 18
Industries AI, Health Care
Funding Stage Seed
Social

Get notified when hema.to GmbH moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About hema.to GmbH

hema.to GmbH, founded in 2021, is a deeptech AI company based in Germany with a mission exemplified by their slogan, "AI cytometry to advance precision immune medicine." The company focuses on innovating within the healthcare sector by leveraging artificial intelligence to enhance cytometry, ultimately aiming to tailor treatment plans to fit the unique immune profiles of individual patients.

Their dedication to transforming immune medicine has attracted financial backing, culminating in a recent €3.60M seed investment on 01 February 2025. This funding round was supported by prominent European investors, including High-Tech Gründerfonds, Bayern Kapital, Elaia Partners, Heal Capital, and LUMO labs. The strategic investment underscores investor confidence in hema.to's potential to make a significant impact on personalized healthcare solutions using cutting-edge AI technologies.

Taxonomy: Deeptech, AI-powered Cytometry, Precision Immune Medicine, Automated Blood Cancer Detection, Flow Cytometry, Healthcare Innovation, Immune System Analysis, Personalized Medicine, Digital Health, Medical Diagnostics, Cancer Treatment Optimization

Services & Products

AI-driven cytometry solutions
Workflow automation
Diagnostic support for B-NHL
Real-time collaborative tools
Cloud-based workflow platforms

Target Customers

Hematology labs Clinical diagnostics labs Medical professionals in hematopathology Research laboratories Laboratories focusing on B-NHL

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed •••••• 5
Investor Investor Investor Investor Investor
01 Feb 2025
Seed •••••• 3
Investor Investor Investor
01 Jun 2023

hema.to GmbH Alternatives & Competitors

View All Alternatives
hema.to GmbH vs
Normunity
Normunity

Biotech company creating a new class of precision immuno-oncology medicines that enable normal immun...

Series A
19 employees
Biotechnology, Health and Wellness
hema.to GmbH vs
Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp. United States

Every immune system has a story to tell; the key is knowing how to listen.

IPO
654 employees
Biotechnology, Health Care
hema.to GmbH vs
Montis Biosciences
Montis Biosciences Belgium

Montis Biosciences develops innovative immune-oncology treatments that focus on the intersection of...

View all alternatives

FAQ About hema.to GmbH

AI cytometry to advance precision immune medicine
hema.to GmbH was founded in 2021.
hema.to GmbH is headquartered in Germany.
hema.to GmbH operates in the following industries: AI, Health Care.
hema.to GmbH has approximately 18 employees.
hema.to GmbH has completed 2 funding rounds, raising a total of $7.20M. The latest funding stage is Seed.
hema.to GmbH offers: AI-driven cytometry solutions, Workflow automation, Diagnostic support for B-NHL, Real-time collaborative tools, Cloud-based workflow platforms.
Top alternatives and competitors to hema.to GmbH include Normunity, Adaptive Biotechnologies Corp., Montis Biosciences, Vaxon Biotech, Repertoire Immune Medicines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
hema.to GmbH and Normunity are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors hema.to GmbH and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy